

Date: October 27, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 544292	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Symbol: ONESOURCE
--	--

Dear Madam/ Sir,

Sub: Press Release:

Please find enclosed herewith Press Release (along with Earnings presentation) issued by the Company titled:

**OneSource Announces Strong Q2FY27 Results
Revenue up 37% YoY and EBITDA up 53% YoY**

You are requested to kindly take the same on record.

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A  Digitally signed by Trisha A
Date: 2026.10.27 10:31:37 +05'30'

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

Encl. as below

OneSource Announces Strong Q2FY27 Results Revenue up 37% YoY and EBITDA up 53% YoY

Performance Highlights

- Revenue of ₹5,162m, up 37% YoY and 15% QoQ, driven by new DDC capacity, strong MSA execution and multiple product launches across all business segments
- EBITDA of ₹1,633m, up 53% YoY and 32% QoQ, with margins expanding to 32%, driven by operating leverage from higher volumes across the business
- Adjusted PAT stood at ₹937m with adjusted EPS of ₹8.2

Bangalore, India, October 27, 2026 – OneSource Specialty Pharma Limited (BSE:544292, NSE: ONESOURCE) today announced its consolidated financial results for the quarter ended September 30, 2026.

Financial Highlights (In ₹ million)

Particulars	Q2FY27	Q2FY26	YoY	Q1FY27	QoQ
Revenues	5,162	3,758	37%	4,490	15%
EBITDA	1,633	1,065	53%	1,233	32%
EBITDA %	31.6%	28.3%	329bps	27.5%	416bps
Adjusted PAT	937	449	109%	637	47%
Adjusted EPS	8.2	3.9	109%	5.6	47%

Note: Adjusted PAT and Adjusted EPS excludes exceptional items (Q2FY27: ₹18m, Q1FY27: ₹43m, Q2FY26: Nil) and scheme related intangible amortisation (₹344m in each quarter)

Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited speaking on the performance said, “Q2 delivered strong sequential growth, led by new DDC capacity. With our second cartridge line commercial, H2 will see new launches and a significant ramp-up in commercial volumes. Biologics momentum remained strong, with yet another US biotech onboarded during the quarter. With additional capacity and partnerships, we are well set for the next phase of growth.”

Detailed investor communication on the performance of the Company is attached.

About OneSource Specialty Pharma Limited

OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,600 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information, please visit www.onesourcecdmo.com.

For further information, please contact:

<u>Institutional Investors</u> Anurag Bhagania CFO Tejaswani Fotedar +91 9004331391 Email: investor-relations@onesourcecdmo.com	<u>Corporate Communication</u> Pallavi Panchmatia: +91 8951939181 Email: pallavi.panchmatia@onesourcecdmo.com Abhilash Mukherjee: +91 89044 28907 Email: abhilash.mukherjee@onesourcecdmo.com Harsh Sheth: +91 9870631557 Email: harsh.sheth@mslgroup.com
--	--

The background of the slide is a photograph of three mountaineers ascending a steep, snow-covered mountain ridge. The sun is low on the horizon, creating a warm, golden glow and long shadows. The sky is filled with soft, white clouds. The mountaineers are silhouetted against the bright light, and their shadows are cast long on the snow. The overall mood is one of achievement and forward progress.

onesource

Building for the Future

Investor Presentation | Q2FY27

October 27, 2026

(The new way to CDMO)



Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", "seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those suggested by the forward- looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

New DDC capacity drives strong YoY revenue and EBITDA growth



(Q2FY27 Performance Snapshot)

₹5,162m

\$54.2m

Revenue



37% YoY



15% QoQ

₹1,633m

\$17.2m

EBITDA



53% YoY



32% QoQ

32%

EBITDA margin



329 bps YoY



416 bps QoQ

₹937m

\$9.8m

Adjusted PAT¹



109% YoY



47% QoQ



“Q2 delivered strong sequential growth, led by new DDC capacity. With our second cartridge line commercial, H2 will see new launches and a significant ramp-up in commercial volumes. Biologics momentum remained strong, with yet another US biotech onboarded during the quarter. With additional capacity and partnerships, we are well set for the next phase of growth.”



Neeraj Sharma
CEO & MD

Notes: All figures presented in \$m have been converted using average exchange rate of USD = ₹95.17

¹ Adjusted PAT excludes exceptional items (Q2FY27: ₹18m) and scheme related intangible amortisation (Q2FY27: ₹344m)

Q2FY27: Revenue up 37% YoY and EBITDA up 53% YoY



In ₹m	Q2FY27	YoY	QoQ	Q1FY27
Revenue	5,162	+37%	+15%	4,490
EBITDA	1,633	+53%	+32%	1,233
EBITDA margin (%)	31.6%	+329bps	+416bps	27.5%
Reported PAT	575	+448%	+130%	250
Adjusted PAT ¹	937	+109%	+47%	637
Adjusted EPS ¹ (₹)	8.2	+109%	+47%	5.6


In \$m	Q2FY27	YoY	QoQ	Q1FY27
Revenue	54.2	+37%	+15%	47.2
EBITDA	17.2	+53%	+32%	13.0
EBITDA margin (%)	31.6%	+329bps	+416bps	27.5%
Reported PAT	6.0	+448%	+130%	2.6
Adjusted PAT ¹	9.8	+109%	+47%	6.7
Adjusted EPS ¹ (\$)	0.09	+109%	+47%	0.06

Notes: All figures presented in \$ have been converted using average exchange rate of USD = ₹95.17 and accordingly the prior period figures have been restated

¹ Adjusted PAT and Adjusted EPS excludes exceptional items (Q2FY27: ₹18m, Q1FY27: ₹43m) and scheme related intangible amortisation (₹344m in each quarter)

Financial Snapshot

- **Revenue of ₹5,162m/ \$54.2m**
↑37% YoY and ↑15% QoQ, our third consecutive quarter of sequential growth. New DDC capacity and MSA execution led the increase, supported by 12 launches and growth across all businesses
- **EBITDA of ₹1,633m/ \$17.2m**
↑ 53% YoY and ↑ 32% QoQ. Operating leverage led to margin expansion, with new capacity providing a runway for volume growth



Business & Operational Updates



Q2FY27

onesource

New capacity coming online as launches and partnerships build across businesses



Key Highlights


DDC Capacity	Second cartridge line commercialised ; line 3 FAT completed
DRL	Approval across multiple markets (LatAm, Africa, the Middle East, Canada and India) API supply in place ; Canada relaunch imminent, other markets to follow
Semaglutide	First generic in KSA launched by Hikma, expanding our global presence Approvals anticipated in multiple new markets (Brazil, Turkey) in next 2 quarters
Biologics	Signed a US partner for integrated DS + DP across multiple programs
Quality	Successfully completed 11 regulatory inspections and customer audits

FAT = Factory Acceptance Test
¹Total number of production days available across all lines

DDC capacity to triple for FY28: Two cartridge lines commercial, line 3 FAT completed



Maintaining cold-chain integrity throughout the sterile manufacturing process



Cartridge filling

Aseptic fill of drug cartridges on the isolator filling line

4

High-speed filling lines

Visual inspection

Automated and manual checks for particulates and defects

3

Fully automated machines

Pen assembly

Cartridge integrated into the pen device at assembly stations

4

Fully automated high-speed machines

Labelling

Serialised primary labels applied with vision verification

Packaging

Pens cartoned with leaflets and cased into finished packs

3

Fully automated lines

Warehousing

Finished packs stored under continuous cold-chain monitoring until dispatch

16k⁺

Pallet storage (1/3rd for cold storage)

Steady State (FY28)

Biologics platform gaining momentum, with new customer wins and robust funnel



Integrated DS-DP-Device



One contract, one audit, no cold-chain handoff between sites

Partner wins and funnel

H1 wins non-exhaustive

BIOSIMILARS

US biopharma partner

End-to-end DS + DP for multiple programs

NEW IN Q2

Formycon

European biosimilar major onboarded

NEW PARTNER

ANIMAL HEALTH

Top-3 global animal health company

3rd project signed with an existing partner

REPEAT BUSINESS

RFP funnel highest ever

Record RFP funnel

Innovators · Biosimilars · Animal health

Late-stage discussions

Multiple, with US and European partners across segments

Converting to wins

New MSAs and repeat projects signed in H1

Business Outlook



onesource

Reaffirming FY28 outlook of \$ 400M organic revenue and \$ 160M EBITDA



\$ 400M

Revenue (organic)

40%

Steady state EBITDA margin

STRATEGIC PILLARS FOR OUR GROWTH

DDCs (including GLP-1s)

Scaling across markets and customers, supported by capacity expansion

BIOLOGICS

Biologics funnel expanding with continued pipeline growth and execution of MSAs

BASE BUSINESS

Sterile injectable and softgel platforms expanding through new capability investments and strong repeat business



(Q2FY27) earnings
call



Schedule:

Day: Tuesday
Date: 27th October 2026
Time: 06:30 PM IST



Speakers:

Neeraj Sharma, CEO & MD
Anurag Bhagania, CFO



Dial In:

+91 22 6280 1372
+91 22 7115 8193



Diamond Pass:

[Click here](#) for early registration


onesource

THE NEW WAY TO CDMO



OneSource at a glance

Building a pure-play CDMO platform, distinguished by extensive capabilities and robust financial metrics



¹: DDC: Drug Device Combination



Latest Rating Updates

NSE Sustainability Ratings & Analytics

“Leader” category among NSE-listed peers

73/100

SES ESG

65.7/100

EcoVadis 64/100 ▲7 in FY25 vs FY24 | Bronze | Top 35%

Environment		67▲7
Labour & Human Rights		66▲6
Ethics		62▲12
Sustainable Procurement		55▲5

CDP Maintained the score consecutively for 2 years

Climate Change	B
Water Security	B

Rewards & Recognition



Sustainability Excellence Award

Received the Sustainability Excellence Award at the 5th National Bharat CSR & Sustainability Awards 2025



Workplace & Contractor Safety Management

Selected for Prestigious Safety Awards by the National Safety Council, Karnataka Chapter for outstanding performance in Workplace Safety and Contractor Safety Management (FY24 and FY25)

Our Sustainability Efforts are aligned to Global Frameworks, Certifications, and Standards



United Nations
Global Compact

INTEGRATED
REPORTING <IR>



ecovadis

onesource

THE NEW WAY TO CDMO

Get in touch with us

REGISTERED AND CORPORATE OFFICE

OneSource Specialty Pharma Ltd

Registered Office:

Unit No. 902, Cyber One, Plot No - 4 & 6, Sector 30A,
Vashi, Navi Mumbai, Sanpada, Thane,
Maharashtra, India, 400703
T: +91 22 2789 2924
F: +91 22 2789 2942

Corporate Office:

OneSource Specialty Pharma Limited
Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road,
Bengaluru, India, 560076
T: +91 80 6784 0738

www.onesourcecdmo.com

INVESTOR RELATIONS

Investor-relations@onesourcecdmo.com